Latest IDEXX News & Updates

See the latest news and media coverage for IDEXX. We track all announcements, press releases, and industry mentions in real time, all in one place.

IDEXX

Veterinary diagnostics and animal health technology company

idexx.com

Headquarters: Westbrook, United States
Founded year: 1983
Company type: Public company
Number of employees: 10,000+
Industry: Medical Equipment, Supplies & Distribution

Last updated Today

Latest news about IDEXX

In short: IDEXX posted strong 2026 growth, expanded cancer diagnostics, and acquired AI firm CoVetAI to enhance its software ecosystem.

Company announcements

October 1 IDEXX

IDEXX announces upcoming third quarter financial results release

The company will report Q3 2026 earnings before market open on November 2, with a conference call available via webcast or phone.

August 4 IDEXX

IDEXX Laboratories announces second quarter 2026 financial results

Revenue grew 10% as reported and 9% organic to $1.22 billion; EPS rose 18% to $4.27; the company raised its full-year guidance.

July 28 IDEXX

IDEXX releases 2025 Corporate Responsibility Report

The report highlights progress on innovation, people, and environmental goals, including GHG emission reductions and access to care.

May 26 IDEXX

IDEXX expands Fecal Dx platform with taeniid tapeworm detection

The expansion adds detection of Taenia and Echinococcus species, broadening intestinal parasite screening in routine care.

Media coverage

September 16 Yahoo Finance

IDEXX Laboratories Acquires Veterinary AI Platform CoVetAI

Learn more IDEXX Laboratories (IDXX) acquired CoVetAI, an AI-powered clinical scribe and workflow platform for veterinary medicine, Chicago Pacific Founders said Wednesday. Financial details weren't...

September 8 Investing.com

IDEX stock hits 52-week low of $517.00

In other recent developments, IDEXX Laboratories reported second-quarter earnings that beat Wall Street expectations, driven by increased demand for diagnostics, improved...

August 20 Yahoo Finance

IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve

IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international...

August 11 Yahoo Finance

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.

Never miss news about IDEXX

Track IDEXX and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.